These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 23617468)
21. Ling et al.'s 'Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder'. Levin FR; Mariani JJ; Bisaga A; Nunes EV Addiction; 2015 May; 110(5):875-6. PubMed ID: 25808040 [No Abstract] [Full Text] [Related]
22. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Morley KC; Cornish JL; Faingold A; Wood K; Haber PS Expert Opin Investig Drugs; 2017 May; 26(5):563-578. PubMed ID: 28351169 [TBL] [Abstract][Full Text] [Related]
23. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Chen H; Wu J; Zhang J; Hashimoto K Curr Drug Abuse Rev; 2010 Dec; 3(4):222-38. PubMed ID: 21208168 [TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Haile CN; Kosten TR; Kosten TA Am J Drug Alcohol Abuse; 2009; 35(3):161-77. PubMed ID: 19462300 [TBL] [Abstract][Full Text] [Related]
25. Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction. Cao DN; Shi JJ; Hao W; Wu N; Li J Eur J Pharmacol; 2016 Jun; 780():129-35. PubMed ID: 27018393 [TBL] [Abstract][Full Text] [Related]
26. Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern. Khoramizadeh M; Effatpanah M; Mostaghimi A; Rezaei M; Mahjoub A; Shishehgar S Daru; 2019 Dec; 27(2):743-753. PubMed ID: 31228128 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials. Lam L; Anand S; Li X; Tse ML; Zhao JX; Chan EW Clin Toxicol (Phila); 2019 Apr; 57(4):225-233. PubMed ID: 30451013 [TBL] [Abstract][Full Text] [Related]
28. [Pharmacological treatment of amphetamine dependence still on unsafe basis]. Franck J Lakartidningen; 2011 Oct 9-15; 108(45):2304-7. PubMed ID: 22242247 [No Abstract] [Full Text] [Related]
29. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Stoops WW; Rush CR Expert Rev Clin Pharmacol; 2014 May; 7(3):363-74. PubMed ID: 24716825 [TBL] [Abstract][Full Text] [Related]
30. Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. Ezard N; Dunlop A; Clifford B; Bruno R; Carr A; Bissaker A; Lintzeris N BMC Psychiatry; 2016 Dec; 16(1):428. PubMed ID: 27905916 [TBL] [Abstract][Full Text] [Related]
31. Breakingtheice: a protocol for a randomised controlled trial of an internet-based intervention addressing amphetamine-type stimulant use. Tait RJ; McKetin R; Kay-Lambkin F; Bennett K; Tam A; Bennett A; Geddes J; Garrick A; Christensen H; Griffiths KM BMC Psychiatry; 2012 Jun; 12():67. PubMed ID: 22731926 [TBL] [Abstract][Full Text] [Related]
32. Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine. Reynolds AR; Strickland JC; Stoops WW; Lile JA; Rush CR Drug Alcohol Depend; 2017 Dec; 181():25-29. PubMed ID: 29028556 [TBL] [Abstract][Full Text] [Related]
33. Commentary on Konstenius et al. (2014): on medication development for stimulant addiction. Shoptaw S Addiction; 2014 Mar; 109(3):450-1. PubMed ID: 24524320 [No Abstract] [Full Text] [Related]
35. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107 [TBL] [Abstract][Full Text] [Related]
36. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867 [TBL] [Abstract][Full Text] [Related]
37. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715 [TBL] [Abstract][Full Text] [Related]
38. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721 [TBL] [Abstract][Full Text] [Related]